The overall objective was to explore if FGF21 could be used safely and efficaciously to treat common obesity-associated metabolic dyscrasias, utilizing a research colony of obese and overweight cats with similar insulin resistance and metabolic alterations. This evidence concerns the gene FGF21 and Obesity.